The global preimplantation genetics diagnosis (PGD) market revenue was around US$ 81,520.2 thousand in 2022 and is estimated to reach US$ 198,603.5 thousand by 2031, growing at a compound annual growth rate (CAGR) of 10.4% during the forecast period from 2023 to 2031.
Preimplantation genetic testing (PGD) is a method for determining genetic problems in in-vitro fertilization (IVF) embryos before pregnancy. In addition, it does tests on embryos to determine whether they are embryos are genetically flawed. PGD is a non-invasive treatment that can be utilized instead of conventional post-conception diagnostic tests.
Market Driving Factors
The global preimplantation genetic testing market is primarily fueled by an increase in infertility rate in individuals, PCOD syndrome in women, lifestyle changes, hereditary genetic disorders in couples, advances in genetics, increase in fertilization treatment facilities and therapies to resolve chromosomal anomalies.
PGD performs as a tool in IVF genetic testing, which aids in the examination of embryos beyond their superficial appearance. PGD significantly decreases the likelihood of conceiving abnormal embryos by executing embryo genetic testing, thereby being a main driving element for market growth. Furthermore, it raises the chances of successful healthy pregnancies. In addition, elements including rising stress levels, increased drug and alcohol use, increased smoking, poor food, environmental pollutants, and an increase in health problems related to hormones have raised infertility cases across the globe. This has increased the demand for IVF, thereby positively influencing the market expansion.
Benefits including the creation of saviour siblings and a rise in the adoption of assisted reproductive technology (ART) in developing nations are predicted to offer the potential for the PGD market growth. Furthermore, rise in the risk of fatal genetic, preimplantation genetics diagnostic market size is growing due to the rise in fatal genetic, hereditary, and chromosomal illnesses like Duchenne muscular dystrophy, cystic fibrosis, triploidy, down syndrome, and thalassemia that motivate patients to choose PGD and drive the market growth.
The scientific developments in emerging countries and lifestyle variations, especially in women's lives, are making them show hormonal changes boost the market for further growth.
High prices related to preimplantation genetic testing are one of the main factors constraining market growth. The healthcare price of preimplantation genetic testing has not been covered by insurance in some countries and the utilization of this testing is poor in such countries, which is slowing the market expansion.
Regional Analysis
Asia Pacific is predicted to dominate the market during the projection period. Emerging nations like India and China are engaged in a variety of advancements based on reproductive health accompanied by the introduction of various supportive legislative laws. The existence of regulatory bodies, like the Japanese Society of Obstetrics and Gynecology (JSOG), which monitor and approves the difficulties related to reproductive health in Japan is predicted to regional expansion. Furthermore, the rise in adoption of IVF procedures transforms into high acceptance of PGT workflow and consequently drives market growth.
Segmentation Insights
Method Insights
The Aneuploidy segment accumulates the highest revenue share in the market. Preimplantation genetic testing for this segment has been suggested as a method to identify full chromosomal aneuploidy before the transfer, potentially rising live birth rates, and reducing early pregnancy failure rates. In addition, it has been broadened to include analysis of all chromosomes using methods like array next-generation sequencing and comparative genomic hybridization.
Prominent Companies
Segmentation Outline
The global preimplantation genetics diagnosis (PGD) market segmentation focuses on Test Type and Region.
By Test Type
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 CHROMOSOMAL ABNORMALITIES
5.3 ANEUPLOIDY
5.4 X-LINKED DISEASES
5.5 SINGLE GENE DISORDERS
5.6 HLA TYPING
5.7 GENDER SELECTION
5.8 OTHERS
6 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY GEOGRAPHY
6.1 OVERVIEW
6.2 NORTH AMERICA
6.2.1 NORTH AMERICA MARKET SNAPSHOT
6.2.2 U.S.
6.2.3 CANADA
6.2.4 MEXICO
6.3 EUROPE
6.3.1 EUROPE MARKET SNAPSHOT
6.3.2 WESTERN EUROPE
6.3.2.1 THE UK
6.3.2.2 GERMANY
6.3.2.3 FRANCE
6.3.2.4 ITALY
6.3.2.5 SPAIN
6.3.2.6 REST OF WESTERN EUROPE
6.3.3 EASTERN EUROPE
6.3.3.1 POLAND
6.3.3.2 RUSSIA
6.3.3.3 REST OF EASTERN EUROPE
6.4 ASIA PACIFIC
6.4.1 ASIA PACIFIC MARKET SNAPSHOT
6.4.2 CHINA
6.4.3 JAPAN
6.4.4 INDIA
6.4.5 AUSTRALIA & NEW ZEALAND
6.4.6 ASEAN
6.4.7 REST OF ASIA PACIFIC
6.5 MIDDLE EAST & AFRICA
6.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
6.5.2 UAE
6.5.3 SAUDI ARABIA
6.5.4 SOUTH AFRICA
6.5.5 REST OF MEA
6.6 SOUTH AMERICA
6.6.1 SOUTH AMERICA MARKET SNAPSHOT
6.6.2 BRAZIL
6.6.3 ARGENTINA
6.6.4 REST OF SOUTH AMERICA
7 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
7.4 COMPETITIVE DASHBOARD
7.5 PRODUCT MAPPING
7.6 TOP PLAYER POSITIONING, 2022
7.7 COMPETITIVE HEATMAP
7.8 TOP WINNING STRATEGIES
8 COMPANY PROFILES
8.1 REPRODUCTIVE GENETIC INNOVATIONS (RGI)
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.2 AGILENT TECHNOLOGIES
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.3 QUEST DIAGNOSTICS
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.4 INVITAE CORPORATION
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.5 PERKINELMER
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.7 ILLUMINA INC
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.8 CEGAT GMBH
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.9 PACGENOMICS
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.10 NATERA INC
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
8.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved